Both are City of Hope sponsored with Mustang Biotech having in-licensed their technology from COH, as CHM has done. Based purely on current data available, the two technologies are line-ball.
Mustang's results are: 50% for DCR - 10.2 mths mdn survival - safety issues overcome via direct delivery into the brain
Chimeric's results are: 55% for DCR - 9.9 mths mdn survival - no safety issues
The above comparison doesn't take into account the fact that the CHM 1101 trial has yet to reach its maximal feasible dose and final patient cohort. Interestingly, CHM initiated a self-sponsored Phase 1B trial before Phase 1A trial completion - essentially to advance it in parallel with the first trial at a site in Texas. Perhaps interim data will be used towards our Ph2 regulatory package submission to the FDA.
- Forums
- ASX - By Stock
- Ann: Clinical milestones for 2024 & 2023 successes highlighted
Both are City of Hope sponsored with Mustang Biotech having...
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
|
|||||
Last
1.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.07M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 539558 | 1.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.8¢ | 30000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 539558 | 0.017 |
17 | 2833886 | 0.016 |
19 | 2586784 | 0.015 |
3 | 708475 | 0.014 |
2 | 222223 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.018 | 30000 | 2 |
0.019 | 1360467 | 5 |
0.020 | 1473093 | 6 |
0.021 | 871092 | 3 |
0.022 | 600000 | 2 |
Last trade - 10.30am 02/09/2024 (20 minute delay) ? |
Featured News
CHM (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online